Study wrapper · #308
Endotypic trait responses to 12-month tirzepatide treatment for an obese patient with obstructive sleep apnea: a case report.
Editor's note
A single-patient case report from within the SURMOUNT-OSA trial: a 35-year-old man with severe obstructive sleep apnoea who, over 12 months of tirzepatide, saw his BMI fall from 31.0 to 24.9 and his apnoea-hypopnoea index drop from 54.8 to 4.4 events per hour, from severe to near-normal. The authors also report favourable shifts in underlying airway physiology (better upper-airway patency, stronger pharyngeal muscle response, lower loop gain), suggesting benefit beyond weight loss alone. The number to keep in view is n=1. A case report can illustrate a mechanism vividly but cannot establish how often, how much, or for whom such a result occurs; individual responses vary widely and single dramatic cases are selectively memorable. The larger SURMOUNT-OSA randomised trial is the appropriate evidence for tirzepatide and sleep apnoea; this vignette is a detailed physiological snapshot nested within that programme, useful for understanding how the effect might work, not for gauging its typical size. Read it as illustrative, not representative.
Plain-language abstract
This is a detailed report on one person, drawn from a larger clinical trial. A 35-year-old man with severe obstructive sleep apnoea (OSA), where the airway repeatedly collapses during sleep, took the medicine tirzepatide for 12 months. His body-mass index dropped from 31.0 to 24.9, and his sleep-apnoea severity score (the apnoea-hypopnoea index, or number of breathing interruptions per hour) fell dramatically from 54.8 to 4.4, moving him from severe to nearly normal. Detailed sleep testing suggested the improvement came not only from weight loss but also from helpful changes in how his airway and breathing control worked: the airway stayed more open, the throat muscles responded better, and his breathing control became more stable. Because this describes just one patient, it cannot tell us how common or how large such results are for other people. It offers a close-up look at how the effect might happen, within a bigger trial that is the proper test of the question.